HC Wainwright Issues Pessimistic Forecast for Avalo Therapeutics (NASDAQ:AVTX) Stock Price

Avalo Therapeutics (NASDAQ:AVTX) had its price objective reduced by analysts at HC Wainwright from $40.00 to $35.00 in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 97.29% from the stock’s current price.

AVTX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Avalo Therapeutics in a report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 target price for the company. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective for the company. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Citigroup reissued an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Finally, Citizens Jmp raised their price objective on shares of Avalo Therapeutics from $52.00 to $62.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.13.

Avalo Therapeutics Trading Down 6.7%

Shares of Avalo Therapeutics stock opened at $17.74 on Thursday. Avalo Therapeutics has a 12-month low of $3.43 and a 12-month high of $24.27. The stock has a market cap of $520.24 million, a PE ratio of -3.25 and a beta of 0.78. The company has a 50-day moving average of $15.83 and a two-hundred day moving average of $16.46.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. On average, sell-side analysts forecast that Avalo Therapeutics will post -3.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the chief financial officer directly owned 423 shares of the company’s stock, valued at approximately $5,596.29. The trade was a 95.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the sale, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 138,078 shares of company stock valued at $2,501,346. Company insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after buying an additional 2,648 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Avalo Therapeutics by 10.6% during the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after buying an additional 95,000 shares during the period. Bank of America Corp DE grew its stake in shares of Avalo Therapeutics by 7,066.8% during the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after buying an additional 400,898 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at $56,000. Finally, Aberdeen Group plc purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at $925,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics News Summary

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target on Avalo Therapeutics to $45 from $39 and maintained an outperform rating, signaling continued optimism about the company’s longer-term potential. Avalo Therapeutics (NASDAQ:AVTX) Given New $45.00 Price Target at Mizuho
• Positive Sentiment: HC Wainwright reiterated a buy rating and set a $35 target, while Citizens JMP kept a market outperform stance with a $55 target, suggesting analysts still see substantial upside despite trimming estimates. Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $55.00 at Citizens Jmp Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $35.00 at HC Wainwright
• Neutral Sentiment: Several firms adjusted their valuation targets in both directions, including Wedbush cutting its target to $34 and Citizens JMP lowering its target to $55, which may be contributing to volatility but does not signal a bearish consensus. Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $34.00 by Analysts at Wedbush
• Negative Sentiment: The company also urged investors to review Form 10-Q risk factors amid ongoing uncertainty, which is likely pressuring shares by reminding the market of regulatory and execution risks. Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.